Italia markets open in 1 hour 23 minutes

Terns Pharmaceuticals, Inc. (TERN)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
7,91-0,17 (-2,10%)
Alla chiusura: 04:00PM EST
7,52 -0,39 (-4,93%)
Dopo ore: 08:00PM EST
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente8,08
Aperto8,04
Denaro0,00 x 1800
Lettera0,00 x 1400
Min-Max giorno7,76 - 8,29
Intervallo di 52 settimane3,26 - 14,04
Volume830.114
Media Volume614.678
Capitalizzazione488,794M
Beta (5 anni mensile)-0,83
Rapporto PE (ttm)N/D
EPS (ttm)-1,13
Prossima data utili25 mar 2024 - 29 mar 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1A14,50
  • GlobeNewswire

    Terns Pharmaceuticals Announces Global Phase 1 Clinical Trial Design of TERN-701 for the Treatment of Chronic Myeloid Leukemia

    Investigational New Drug application cleared by U.S. Food and Drug Administration Design leverages insights from partner’s ongoing Phase 1 trial in China that support starting dose that appears safe and clinically active based on emerging early clinical data Patient screening anticipated in December 2023, with initial data expected in second half of 2024 FOSTER CITY, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage

  • GlobeNewswire

    Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

    FOSTER CITY, Calif., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, non-alcoholic steatohepatitis (NASH) and obesity, today announced that it has granted as of October 1, 2023 equity inducement awards to two new non-executive employees under the terms of the 2022 Employment Inducement Awar

  • GlobeNewswire

    Terns Pharmaceuticals to Participate in Upcoming September Investor Conferences

    FOSTER CITY, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, non-alcoholic steatohepatitis (NASH) and obesity, today announced that members of senior management will be participating in the following upcoming investor conferences in September. 2023 Wells Fargo Healthcare Conference